Switch theme
Sign up to access all valuation multiples
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
1999
n/a
LTM Revenue $6.6M
LTM EBITDA -$8.2M
$28.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Actinogen Medical has a last 12-month revenue (LTM) of $6.6M and a last 12-month EBITDA of -$8.2M.
In the most recent fiscal year, Actinogen Medical achieved revenue of n/a and an EBITDA of -$8.1M.
Actinogen Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Actinogen Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $6.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$8.2M | XXX | -$8.1M | XXX | XXX | XXX |
| EBITDA Margin | -126% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$8.5M | XXX | -$14.9M | XXX | XXX | XXX |
| EBIT Margin | -130% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$8.4M | XXX | -$8.4M | XXX | XXX | XXX |
| Net Margin | -128% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Actinogen Medical's stock price is AUD 0 (or $0).
Actinogen Medical has current market cap of AUD 66.7M (or $42.9M), and EV of AUD 44.1M (or $28.4M).
See Actinogen Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.4M | $42.9M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Actinogen Medical has market cap of $42.9M and EV of $28.4M.
Actinogen Medical's trades at n/a EV/Revenue multiple, and -3.8x EV/EBITDA.
Equity research analysts estimate Actinogen Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Actinogen Medical has a P/E ratio of -5.1x.
See valuation multiples for Actinogen Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42.9M | XXX | $42.9M | XXX | XXX | XXX |
| EV (current) | $28.4M | XXX | $28.4M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | -3.8x | XXX | XXX | XXX |
| EV/EBIT | -3.3x | XXX | -2.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.1x | XXX | -5.6x | XXX | XXX | XXX |
| EV/FCF | -2.6x | XXX | -3.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialActinogen Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Actinogen Medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Actinogen Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Actinogen Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -126% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Actinogen Medical acquired XXX companies to date.
Last acquisition by Actinogen Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Actinogen Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Actinogen Medical founded? | Actinogen Medical was founded in 1999. |
| Where is Actinogen Medical headquartered? | Actinogen Medical is headquartered in Australia. |
| Is Actinogen Medical publicy listed? | Yes, Actinogen Medical is a public company listed on ASX. |
| What is the stock symbol of Actinogen Medical? | Actinogen Medical trades under ACW ticker. |
| When did Actinogen Medical go public? | Actinogen Medical went public in 2007. |
| Who are competitors of Actinogen Medical? | Similar companies to Actinogen Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Actinogen Medical? | Actinogen Medical's current market cap is $42.9M |
| What is the current revenue of Actinogen Medical? | Actinogen Medical's last 12 months revenue is $6.6M. |
| What is the current EV/Revenue multiple of Actinogen Medical? | Current revenue multiple of Actinogen Medical is 4.3x. |
| Is Actinogen Medical profitable? | Yes, Actinogen Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Actinogen Medical? | Actinogen Medical's last 12 months EBITDA is -$8.2M. |
| What is Actinogen Medical's EBITDA margin? | Actinogen Medical's last 12 months EBITDA margin is -126%. |
| What is the current EV/EBITDA multiple of Actinogen Medical? | Current EBITDA multiple of Actinogen Medical is -3.4x. |
| What is the current FCF of Actinogen Medical? | Actinogen Medical's last 12 months FCF is -$10.9M. |
| What is Actinogen Medical's FCF margin? | Actinogen Medical's last 12 months FCF margin is -166%. |
| What is the current EV/FCF multiple of Actinogen Medical? | Current FCF multiple of Actinogen Medical is -2.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
